Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, and its partner, Genostics Company Limited, today announced the start of a multi-centre case control study on early lung cancer detection (for screening and nodules) in the People’s Republic of China using an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells in Asian populations.
Dr Adam M Hill, CEO of Oncimmune commented: “This study is part of our ongoing programme to support the introduction of EarlyCDT-Lung in China, which is progressing to schedule. We welcome this initiative and the commitment of our partner Genostics in supporting the introduction of EarlyCDT-Lung into what is one of the world’s largest markets.”
The study will be led by Professor Bai, Professor and Chair of the Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University and will study approximately 1,000 early lung cancers at five leading academic health centres across China. The results are expected in the fourth quarter of 2019 and will be used to support Oncimmune’s application for approval of EarlyCDT-Lung with the China Food and Drug Administration.
Dr Cheung To, Chairman of Gene Group, said: “For more than 20 years, we have been committed to bringing the world’s most cutting-edge technologies and products into China. EarlyCDT-Lung is a unique and innovative product. This China-wide validation study in the Chinese population will help with EarlyCDT-Lung’s future effective commercialisation and accelerate the introduction of an early lung cancer screening program in China, benefiting Chinese patients and families.”